Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
- Revenue in AUD (TTM)92.97m
- Net income in AUD-134.18m
- Incorporated2004
- Employees81.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PYC Therapeutics Ltd | 24.52m | -47.56m | 1.90bn | 23.00 | -- | 5.96 | -- | 77.43 | -0.0836 | -0.0836 | 0.0429 | 0.2464 | 0.2157 | -- | 1.09 | -- | -42.46 | -42.88 | -47.19 | -47.98 | -- | -- | -196.86 | -172.76 | -- | -25.46 | 0.0056 | -- | 14.51 | 58.66 | -33.34 | -- | 55.85 | -- |
| Rubicon Research Ltd | 245.21m | 31.64m | 1.93bn | 1.14k | 58.42 | -- | 51.29 | 7.87 | 13.07 | 13.07 | 102.06 | -- | -- | -- | -- | 14,424,080.00 | -- | -- | -- | -- | 68.82 | -- | 12.90 | -- | -- | 12.92 | -- | -- | 50.40 | -- | 47.63 | -- | -- | -- |
| HitGen Inc | 102.16m | 23.38m | 2.15bn | 483.00 | 92.65 | 7.13 | -- | 21.03 | 0.2824 | 0.2824 | 1.24 | 3.67 | 0.2726 | 6.37 | 4.69 | 1,032,114.00 | 6.18 | 3.06 | 6.87 | 3.36 | 55.23 | 53.55 | 22.67 | 14.48 | 5.12 | 6.59 | 0.1674 | 34.32 | 14.99 | 10.08 | 26.13 | -15.65 | 3.16 | -- |
| InventisBio Co Ltd | 36.99m | -23.83m | 2.34bn | 185.00 | -- | 6.86 | -- | 63.24 | -0.2012 | -0.2012 | 0.3122 | 2.88 | 0.0988 | -- | 1.03 | 975,824.70 | -6.36 | -32.89 | -6.76 | -35.22 | 99.41 | -- | -64.41 | -682.73 | -- | -- | 0.0127 | -- | -9.02 | 25.00 | 15.41 | -- | -3.97 | -- |
| Onesource Specialty Pharma Ltd | 217.77m | 3.19m | 2.35bn | 1.41k | 734.28 | -- | 51.61 | 10.78 | 1.82 | 1.76 | 129.84 | -- | -- | -- | -- | 10,051,880.00 | -- | -- | -- | -- | 70.99 | -- | 1.46 | -- | -- | 0.8886 | -- | -- | 740.43 | -- | 95.27 | -- | -- | -- |
| Syngene International Ltd | 570.78m | 54.02m | 2.47bn | 6.53k | 45.93 | -- | 20.31 | 4.33 | 8.72 | 8.72 | 92.16 | -- | -- | -- | -- | 5,694,474.00 | -- | 8.14 | -- | 10.44 | 75.26 | 71.29 | 9.46 | 15.03 | -- | 5.73 | -- | -- | 4.41 | 12.60 | -2.71 | 3.78 | 3.67 | -- |
| Keymed Biosciences Inc | 178.36m | -52.62m | 2.50bn | 1.47k | -- | 3.83 | -- | 14.03 | -1.11 | -1.11 | 3.75 | 12.10 | 0.2068 | 0.3382 | 15.10 | 784,218.30 | -6.10 | -40.63 | -7.27 | -44.60 | 95.19 | -- | -29.48 | -593.20 | 3.74 | -- | 0.2145 | -- | 20.91 | -- | -43.38 | -- | 28.05 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 127.98m | -194.16m | 2.57bn | 1.36k | -- | 16.48 | -- | 20.08 | -2.37 | -2.37 | 1.56 | 1.90 | 0.1384 | 0.3458 | 14.57 | 441,048.00 | -21.06 | -29.90 | -36.19 | -36.18 | 88.72 | 85.56 | -152.14 | -1,188.68 | 0.8093 | -10.82 | 0.7353 | -- | 56.28 | 46.68 | 0.9031 | -- | 12.25 | -- |
| Mesoblast Ltd | 92.97m | -134.18m | 2.61bn | 81.00 | -- | 3.19 | -- | 28.04 | -0.1047 | -0.1047 | 0.0725 | 0.6342 | 0.0911 | 1.20 | 2.95 | 1,147,748.00 | -13.15 | -13.19 | -15.28 | -14.68 | 57.98 | -132.14 | -144.33 | -957.40 | 1.41 | -4.74 | 0.1904 | -- | 191.39 | -11.76 | -16.13 | -- | -20.16 | -- |
| Ascentage Pharma Group International | 79.88m | -237.05m | 2.80bn | 605.00 | -- | 19.22 | -- | 35.05 | -4.01 | -4.01 | 1.35 | 2.16 | 0.1270 | 3.70 | 0.9505 | 779,214.40 | -37.68 | -30.84 | -60.56 | -41.94 | 90.87 | 94.02 | -296.81 | -252.93 | 1.53 | -- | 0.7174 | -- | 341.77 | 132.25 | 56.20 | -- | -21.49 | -- |
| Telix Pharmaceuticals Ltd | 1.14bn | -10.13m | 3.21bn | 1.12k | -- | 5.43 | 156.90 | 2.81 | -0.03 | -0.03 | 3.38 | 1.74 | 0.7639 | 13.90 | 7.44 | 1,020,438.00 | -0.6772 | -4.82 | -0.8545 | -6.41 | 47.51 | 55.04 | -0.8864 | -5.75 | 1.27 | 3.64 | 0.5293 | -- | 55.61 | 195.18 | -121.15 | -- | 202.38 | -- |
| Sinocelltech Group Ltd | 386.82m | -63.56m | 3.37bn | 2.28k | -- | -- | -- | 8.70 | -0.6964 | -0.6964 | 4.24 | -0.1083 | 0.5458 | 0.4325 | 3.04 | 828,989.10 | -8.37 | -22.66 | -29.60 | -48.25 | 93.51 | 95.52 | -15.33 | -42.96 | 0.5008 | -0.6753 | 1.02 | -- | 33.13 | 294.24 | 127.39 | -- | 23.95 | -- |
Data as of Mar 05 2026. Currency figures normalised to Mesoblast Ltd's reporting currency: Australian Dollar AUD
15.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| State Street Global Advisors, Australia, Ltd.as of 08 Dec 2025 | 44.97m | 3.49% |
| M&G Investment Management Ltd.as of 31 Oct 2025 | 40.86m | 3.17% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 34.87m | 2.70% |
| Vanguard Investments Australia Ltd.as of 31 Jan 2026 | 19.14m | 1.48% |
| Thorney Investment Group Australia Pty Ltd.as of 30 Sep 2025 | 14.12m | 1.09% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 12.25m | 0.95% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 12.07m | 0.94% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 9.09m | 0.71% |
| BetaShares Capital Ltd.as of 30 Jan 2026 | 7.33m | 0.57% |
| DFA Australia Ltd.as of 31 Jan 2026 | 7.20m | 0.56% |
More ▼
Data from 31 Dec 2025 - 27 Feb 2026Source: FactSet Research Systems Inc.
